Advanced search
Publication Cover
Expert Review of Hematology Volume 6, 2013 - Issue 5
Submit an article Journal homepage
37
Views
5
CrossRef citations to date
0
Altmetric
Key Paper Evaluations

Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

Amer M ZeidanDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, CRB1 Building, Room 186, Baltimore, MD 21287, USACorrespondence[email protected]
&
Steven D GoreDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, CRB1 Building, Room 186, Baltimore, MD 21287, USA
Pages 539-542 | Published online: 10 Jan 2014

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Eytan M. Stein, Gaetano Bonifacio, Dominick Latremouille-Viau, Sherry Shi, Annie Guerin, Eric Q. Wu, Islam Sadek & Xiting Cao. (2021) Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Leukemia & Lymphoma 62:6, pages 1411-1421.
Read now
Nora Chokr, Alexander B. Pine, Jan Philipp Bewersdorf, Rory M. Shallis, Maximilian Stahl & Amer M. Zeidan. (2019) Getting personal with myelodysplastic syndromes: is now the right time?. Expert Review of Hematology 12:4, pages 215-224.
Read now
Abdallah Abou Zahr, Ehab Saad Aldin, Lisa Barbarotta, Nikolai Podoltsev & Amer M Zeidan. (2015) The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Review of Anticancer Therapy 15:9, pages 1019-1036.
Read now

Articles from other publishers (2)

Amer M. Zeidan, Maximilian Stahl, Mikkael A. Sekeres, David P. Steensma, Rami S. Komrokji & Steven D. Gore. (2017) A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer 123:19, pages 3662-3672.
Crossref
Amer M. Zeidan, Ju-Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, Elisabeth Paietta, Janice Gabrilove, Harry P. Erba, Rhett P. Katterling, Martin S. Tallman & Steven D. Gore. (2014) Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. British Journal of Haematology 167:1, pages 62-68.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.